Translational Medicine is driven by our patients, their diseases and a quest to ethically do more than available Evidence Based Medicine.
It is a disruptive yet systematic endeavour guided by a primary focus towards translational sciences spanning across the spectrum of molecular and cell biology to preclinical models to patient studies and back again, following the principles of critical path analysis and a six-sigma framework.
The Department of Translational Medicine and Therapeutics integrates resources and enable researchers at HCG to be at the forefront of scientific discovery and clinical development. It is equipped with an early phase clinical trial centre, pre-clinical study capabilities, regulatory expertise, a clinical trial network, medical & scientific writing team and oncology analytics capabilities and works closely with genomic researchers and clinical scientists.
Department of Translational Medicine and Therapeutics (TMT) at HCG shall be a Centre of Excellence that speeds up the rate at which oncology research can improve patient treatments and outcomes by using an inter-disciplinary, highly-collaborative approach that will include all components of the bench-to-bedside to market pathway and vice-versa.
Department of Translational Medicine and Therapeutics (TMT) at HCG will create integrated and sustainable research enterprise for viability and excellence in Patient Oriented and Outcome Based Research. It shall provide innovative, high-quality, cost-effective, non-clinical and clinical development services and place HCG on the World Map of Oncology Research.
The department supports all the in-house basic and clinical translational research and has an international second opinion network for patient benefit worldwide. Apart from the in-house research activities the department functions as an interface with the Pharma-Biotech industry and makes HCG their preferred partner in oncology drug development programs across the product life cycles.
The department has developed a close relationship with the “Indian Society for Clinical Research (ISCR)” as an Accredited Member Organization of the society. HCG has one nominated member on each of the ISCR councils. As an accredited member of ISCR HCG is at the forefront of Clinical Research activities in the country and also a contributor towards policy development and awareness campaigns (with public, media, legislature and judiciary) regarding cancer clinical research in the country.
The Department of Translational Medicine (TMT) provides services that promote a vibrant translational research and training environment at HCG.
Translational Medicine Services
Early Phase Clinical Research Unit (CRU)
Early Phase Oncology Study Design and Data Management
Internal and International Second Opinion with a scientific deep dive into rare and recurrent cases
Investigator Initiated Studies / Real-world Research
In-vitro and In-vivo non-clinical proof of concept studies / Pharmacology Studies
Regulatory Guidance and Support
Scientific due diligence
Clinical Data Analysis
Medical and Scientific Writing
Research Education and Workforce Development
Translational Oncology – Solid tumours and Hemato-oncology
Cell based therapies
Tumour Microenvironment Interactions
Translational Pathology and Digital Pathology
Genomic theragnostics (Genotype guided cancer therapy)
Diagnostics Development and Drug Screening
Preventive Oncology, Community Engagement and Population Science